Sarepta Therapeutics, Inc. (SRPT - Free Report) posted a loss of $1.15 per share in the third quarter of 2016, narrower than the year-ago loss of $1.25. The Zacks Consensus Estimate reported a loss of $1.35 per share.
No revenue was recorded by the company in the reported quarter, as was the case a year ago. The Zacks Consensus Estimate for revenues was $6 million.
Other Details
Research and development expenses registered a decline of 6.5% on a year-over-year basis to $34.3 million, whereas general and administrative expenses surged 47% to $22.2 million.
Sarepta recently gained accelerated approval for Exondys 51 for the treatment of patients suffering from Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
Meanwhile, Sarepta announced that it has dosed the first patient in a phase III study on SRP-4045 and SRP-4053, which is evaluating patients with DMD amenable to exon 45 or 53 skipping.
Zacks Rank & Key Picks
Sarepta currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include BioMarin Pharmaceutical Inc. (BMRN - Free Report) , Geron Corporation (GERN - Free Report) and Exelixis, Inc. (EXEL - Free Report) . While BioMarin and Geron sport a Zacks Rank #1 (Strong Buy), Exelixis carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BioMarin’s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.
Geron has posted a positive earnings surprise in all of the four trailing quarters with an average beat of 20.8%.
Exelixis’ loss estimates have narrowed from 71 cents to 63 cents for 2016 and from 19 cents to a gain of 2 cents for 2017 over the last 60 days. The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9.1%. Its share price has surged 93.6% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Sarepta Therapeutics, Inc. (SRPT - Free Report) posted a loss of $1.15 per share in the third quarter of 2016, narrower than the year-ago loss of $1.25. The Zacks Consensus Estimate reported a loss of $1.35 per share.
No revenue was recorded by the company in the reported quarter, as was the case a year ago. The Zacks Consensus Estimate for revenues was $6 million.
Other Details
Research and development expenses registered a decline of 6.5% on a year-over-year basis to $34.3 million, whereas general and administrative expenses surged 47% to $22.2 million.
Sarepta recently gained accelerated approval for Exondys 51 for the treatment of patients suffering from Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
Meanwhile, Sarepta announced that it has dosed the first patient in a phase III study on SRP-4045 and SRP-4053, which is evaluating patients with DMD amenable to exon 45 or 53 skipping.
Zacks Rank & Key Picks
Sarepta currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include BioMarin Pharmaceutical Inc. (BMRN - Free Report) , Geron Corporation (GERN - Free Report) and Exelixis, Inc. (EXEL - Free Report) . While BioMarin and Geron sport a Zacks Rank #1 (Strong Buy), Exelixis carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BioMarin’s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.
Geron has posted a positive earnings surprise in all of the four trailing quarters with an average beat of 20.8%.
Exelixis’ loss estimates have narrowed from 71 cents to 63 cents for 2016 and from 19 cents to a gain of 2 cents for 2017 over the last 60 days. The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9.1%. Its share price has surged 93.6% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMRN - FREE
Get the latest research report on GERN - FREE
Get the latest research report on EXEL - FREE
Get the latest research report on SRPT - FREE